Published September 2020 | Version v1
Journal article

Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes

Contributors

Others:

Description

Introduction: KRAS mutations are detected in 20% to 30% of NSCLC. However, KRAS mutation subtypes may differently influence the outcome of patients with advanced NSCLC. Conclusions: KRAS mutation subtypes influenced neither treatment responses nor outcomes. The KRAS G12C mutation was detected in 41.5% of patients, who are now eligible for potent and specific G12C inhibitors.

Abstract

International audience

Additional details

Identifiers

URL
https://hal-amu.archives-ouvertes.fr/hal-03430888
URN
urn:oai:HAL:hal-03430888v1

Origin repository

Origin repository
UNICA